组织驻留记忆T细胞在肺癌中的研究进展

Advances in the Study of Tissue-resident Memory T Cells in Lung Cancer

免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)虽然广泛用于肺癌的治疗,但获益人群有限,且缺乏有效的疗效预测标志物。组织驻留记忆T细胞(tissue-resident memory T cell,TRM)通过表达整合素CD103、CD49a或C型凝集素CD69和免疫检查点受体,使其在组织中驻留,并发挥抗肿瘤作用。表达程序性死亡受体1(programmed cell death 1,PD-1)的TRM富含与细胞毒性相关的转录产物,增强了T细胞(抗原)受体(T cell receptor,TCR)介导的细胞毒作用。TRM可以预测肺癌患者免疫治疗疗效和预后,是具有前景的生物标志物。本综述将阐述TRM在肺癌中的研究进展。

Immune checkpoint inhibitors(ICIs)have been widely used in the treatment of lung cancer,but the benefit population is limited and there is a lack of effective predictive markers of efficacy.Tissue-resident memory T cells(TRM)reside in tissues and exert anti-tumor effects by expressing the integrins CD103,CD49a or C-type lectin CD69 and immune checkpoint receptors.TRM expressing programmed cell death 1(PD-1)is enriched with transcriptional products associated with cytotoxicity and enhances T cell(antigen)receptor(TCR)-mediated cytotoxicity.TRM is a promising biomarker for predicting the efficacy and prognosis of immunotherapy in lung cancer patients.This review will describe the progress of TRM research in lung cancer.